Back to top
more

Vir Biotechnology (VIR)

(Delayed Data from NSDQ)

$10.22 USD

10.22
1,241,862

-0.17 (-1.64%)

Updated May 6, 2024 04:00 PM ET

After-Market: $10.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VIR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Vir Biotechnology, Inc. [VIR]

Reports for Purchase

Showing records 21 - 40 ( 49 total )

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

05/12/2022

Company Report

Pages: 10

Amid COVID-19 Uncertainty, Robust Capital Position Should Enable Value Realization of Pipeline; Lowering PT to $125

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

05/02/2022

Company Report

Pages: 52

Emerging HBV Program With Best-in-Class Traits Should Offset Potential Shortfall in COVID-19 Franchise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 50.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

03/31/2022

Daily Note

Pages: 3

Potential Multi-Blockbuster Chronic HBV Program Further Validated at APASL 2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

03/30/2022

Company Report

Pages: 8

Although Higher Sotrovimab Dose May Maintain Activity Against SARS-CoV-2, FDA Amends EUA; PT to $200; Maintain Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

03/03/2022

Company Report

Pages: 9

4Q21 Results; Sotrovimab Continues to Shine on the COVID-19 Stage; HBV, HIV, Flu Programs on Track With 2022 Catalysts

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

01/31/2022

Company Report

Pages: 8

Upping Near-Term Revenue Estimates on Robust Sotrovimab Uptake; Broad Pipeline on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

12/21/2021

Company Report

Pages: 12

And Then There Was One; Potent Antiviral Sotrovimab to Soften Global Omicron Crisis; Upping PT to $300; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

12/08/2021

Company Report

Pages: 10

Sotrovimab Leads Race to Treat High-Risk SARS-CoV-2 Patients With Positive Preclinical Omicron Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

11/30/2021

Company Report

Pages: 16

Well-Positioned for Robust Prophylaxis and Post-Infection COVID-19 Antiviral Market; Upping PT to $200; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

09/30/2021

Daily Note

Pages: 3

Confirms 660,000 Doses of Sotrovimab Have Been Reserved, Implying Potential Blockbuster COVID-19 Revenues

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for VIR

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

08/10/2021

Company Report

Pages: 9

2Q21 Results; Broad Antiviral Pipeline Progressing; Sotrovimab Well-Positioned Amid Spike in COVID-19 Cases

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

06/28/2021

Company Report

Pages: 11

Positive HBV Program Updates From EASL; Additional Data Updates Expected 2H21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

06/21/2021

Daily Note

Pages: 3

Sotrovimab''s Robust Efficacy in Early Disease COVID-19 Confirmed; NIH Guidelines Reflect Differentiation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

05/27/2021

Daily Note

Pages: 3

Sotrovimab EUA Validates Vir''s Antiviral Platform, Sets Stage for Global Rollout; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

05/27/2021

Daily Note

Pages: 3

Sotrovimab EUA Validates Vir''s Antiviral Platform, Sets Stage for Global Rollout; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

05/20/2021

Company Report

Pages: 7

1Q21 Results; Broad Pipeline Progress; Expect Potential EUA on COVID Antibody in 2H21, Key HBV Updates at EASL in June

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

03/08/2021

Company Report

Pages: 39

Prepare for Takeoff; COMET-ICE Data to Reinvigorate Confidence in COVID-19 Program; PT to $135

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 75.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

03/03/2021

Daily Note

Pages: 3

ACTIV-3 Trial Outcome Consistent With Other mAb; Focus Shifts to Phase 3 Data in Early Treatment of COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Vir Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

01/27/2021

Daily Note

Pages: 3

Best-in-Class Attributes of SARS-CoV-2 Antibodies on Display With Lilly Collaboration; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party